Abstract
The consequences of estrogen deprivation and therapeutic interventions such as radiation, chemotherapy and surgery have a significant negative impact on libido, sexual arousal, orgasmic function and the ability to have pleasurable intercourse. Evaluation and treatment of female sexual dysfunction is a significant unmet need in the breast cancer survivor in spite of the availability of safe and effective treatments.
| Original language | English (US) |
|---|---|
| Title of host publication | Cancer Treatment and Research |
| Publisher | Springer International Publishing |
| Pages | 167-189 |
| Number of pages | 23 |
| DOIs | |
| State | Published - Jan 1 2018 |
Publication series
| Name | Cancer Treatment and Research |
|---|---|
| Volume | 173 |
| ISSN (Print) | 0927-3042 |
Fingerprint
Keywords
- DHEA
- Dyspareunia
- Female sexual dysfunction
- Fractional CO2 laser
- Genitourinary syndrome of menopause
- Hypoactive sexual desire disorder
- Ospemifene
- Prasterone
- Vaginal estrogen
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
}
Sexual function post-breast cancer. / Streicher, Lauren F; Simon, James A.
Cancer Treatment and Research. Springer International Publishing, 2018. p. 167-189 (Cancer Treatment and Research; Vol. 173).Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Sexual function post-breast cancer
AU - Streicher, Lauren F
AU - Simon, James A.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The consequences of estrogen deprivation and therapeutic interventions such as radiation, chemotherapy and surgery have a significant negative impact on libido, sexual arousal, orgasmic function and the ability to have pleasurable intercourse. Evaluation and treatment of female sexual dysfunction is a significant unmet need in the breast cancer survivor in spite of the availability of safe and effective treatments.
AB - The consequences of estrogen deprivation and therapeutic interventions such as radiation, chemotherapy and surgery have a significant negative impact on libido, sexual arousal, orgasmic function and the ability to have pleasurable intercourse. Evaluation and treatment of female sexual dysfunction is a significant unmet need in the breast cancer survivor in spite of the availability of safe and effective treatments.
KW - DHEA
KW - Dyspareunia
KW - Female sexual dysfunction
KW - Fractional CO2 laser
KW - Genitourinary syndrome of menopause
KW - Hypoactive sexual desire disorder
KW - Ospemifene
KW - Prasterone
KW - Vaginal estrogen
UR - http://www.scopus.com/inward/record.url?scp=85041066923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041066923&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-70197-4_11
DO - 10.1007/978-3-319-70197-4_11
M3 - Chapter
C2 - 29349764
AN - SCOPUS:85041066923
T3 - Cancer Treatment and Research
SP - 167
EP - 189
BT - Cancer Treatment and Research
PB - Springer International Publishing
ER -